Ascendis Pharma A/S (NASDAQ:ASND) Releases Quarterly Earnings Results, Beats Expectations By $0.64 EPS

Ascendis Pharma A/S (NASDAQ:ASND) announced its earnings results on Wednesday. The biotechnology company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.64, Zacks reports.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND traded up $6.63 during midday trading on Wednesday, hitting $126.14. 838,244 shares of the company’s stock traded hands, compared to its average volume of 456,285. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00. The stock has a market capitalization of $7.66 billion, a price-to-earnings ratio of -15.61 and a beta of 0.64. The firm has a fifty day moving average of $132.08 and a 200 day moving average of $132.26.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Stifel Nicolaus upped their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday, November 15th. TD Cowen reduced their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. JPMorgan Chase & Co. upped their price objective on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Oppenheimer reduced their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $191.57.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.